Status:
UNKNOWN
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
Lead Sponsor:
MiCareo Taiwan Co., Ltd.
Collaborating Sponsors:
Taipei Veterans General Hospital, Taiwan
Conditions:
CTC and Tumor Related Rare Cell
Eligibility:
All Genders
20+ years
Brief Summary
The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective i...
Eligibility Criteria
Inclusion
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
- Over 20 years of age.
- Cancer patients on immune checkpoint inhibitors.
Exclusion
- Subjects who have other cancer history
- Pregnant females
- Subjects with active, known or suspected autoimmune disease.
- Known history of human immunodeficiency virus (HIV)
Key Trial Info
Start Date :
May 24 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03434912
Start Date
May 24 2017
End Date
April 30 2020
Last Update
August 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan, 11217